Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease

✍ Scribed by Susan Fox; Montague Silverdale; Mark Kellett; Rhys Davies; Malcolm Steiger; Nicholas Fletcher; Alan Crossman; Jonathan Brotchie

• Book ID: 102945016
• Publisher: John Wiley and Sons
• Year: 2004
• Tongue: English
• Weight: 533 KB
• Volume: 19
• Category: Article
• ISSN: 0885-3185
• DOI: 10.1002/mds.10693

✦ Synopsis

Abstract

Opioid peptide transmission is enhanced in the striatum of animal models and Parkinson's disease (PD) patients with levodopa‐induced motor complications. Opioid receptor antagonists reduce levodopa‐induced dyskinesia in primate models of PD; however, clinical trials to date have been inconclusive. A double‐blind, placebo controlled, crossover design study in 14 patients with PD experiencing motor fluctuations was carried out, using the non‐subtype‐selective opioid receptor antagonist naloxone. Naloxone did not reduce levodopa‐induced dyskinesia. The duration of action of levodopa was increased significantly by 17.5%. Non‐subtype‐selective opioid receptor antagonism may prove useful in the treatment of levodopa‐related wearing‐off in PD but not in dyskinesia. © 2003 Movement Disorder Society